NTLA
Intellia Therapeutics Inc
13.10$
+3.7%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -845.4% | – | -417.0% | -836.4% | -931.1% | -661.8% | -895.7% | -699.3% | -558.0% | -301.0% | -779.8% | -1,085.2% | -582.5% | |
| 19.1% | – | 8.7% | 37.4% | 28.6% | 19.9% | 15.0% | 17.4% | 35.8% | 1.6% | 14.6% | 27.2% | 16.1% | |
| 294.8% | – | 118.1% | 587.3% | 434.8% | 307.7% | 131.4% | 154.7% | 142.2% | 394.5% | 89.6% | 236.0% | 238.5% | |
| -114.2% | – | -102.7% | 425.8% | 109.1% | 15.8% | -353.5% | -139.5% | 32.0% | 2.1% | -247.0% | 54.2% | -47.2% | |
| 36.1% | – | 8.7% | 14.5% | 14.0% | 7.6% | 4.4% | 1.7% | 0.2% | 0.5% | 0.5% | 23.6% | 3.4% | |
| 662.9% | – | 20.4% | -347.7% | -84.6% | 1,177.3% | 567.3% | 750.5% | -5.4% | 119.6% | 440.7% | -1,848.4% | -81.5% | |
| 159.3% | – | 207.3% | 592.9% | 902.1% | 18.0% | 0.0% | 102.9% | 833.4% | 8.6% | 223.1% | 2,560.6% | 582.3% | |
| -23.2% | – | -189.3% | -591.2% | -113.6% | 533.5% | -328.4% | 154.0% | 270.0% | -164.8% | -138.0% | -373.0% | -84.1% | |
| -881.5% | – | -425.7% | -850.9% | -945.2% | -669.4% | -900.1% | -701.0% | -558.2% | -301.6% | -780.3% | -1,108.8% | -586.0% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.